For more than two decades, the manufacturing location sites of abortion pill manufacturer Danco Laboratories have been undisclosed, as have the company’s executives, investors and office locations. But according to a recent ABC News interview with Danco spokespersons, the deadly abortion drug is currently being manufactured in Europe, not China, as was reported in years past.
Despite the fact that abortion drugs are marketed and sold to minors, the Food and Drug Administration (FDA) has repeatedly refused to divulge its manufacturing locations. “The FDA concluded that there is a risk that individuals associated with the development, marketing and distribution of mifepristone for medical termination of early pregnancy may become the targets of threats of harm or violence,” the agency told ABC News in a statement. “Therefore, the agency does not disclose the names or locations of such individuals.”
But according to the same ABC News report, a spokesperson for Danco admitted the drug was manufactured in Europe.
“Danco will only disclose that the company’s headquarters is located in New York City, while the drug itself is produced out of facilities in Europe that are inspected by U.S. federal officials,” Danco’s spokesperson told ABC News.
Abortion pill previously manufactured in China
In 1993, President Clinton signed an executive order directing the FDA to expedite marketing of RU-486. In 1994, his administration pressured the French pharmaceutical manufacturer Roussel-Uclaf to assign the U.S. rights of marketing and distribution to the Population Council. This eugenics-founded “non-profit” brought the abortion pill into the U.S. and later set up the pill’s manufacturer, Danco Laboratories, LLC, a sub-licensee of the Population Council.
In 2000, China officials confirmed the Shanghai-based Hua Lian Pharmaceutical Co. was manufacturing the raw compound for RU-486, as the abortion pill was called at the time. This pharmaceutical company was owned by the Chinese Communist Party. The Los Angeles Times also confirmed the location, writing, “Danco refuses to release the names of its executives and investors. The company even persuaded the Food and Drug Administration to keep secret the location of the factory where the abortion drug will be produced, despite several published reports that it will be made in bulk at the state-owned Hua Lian Pharmaceutical Co. in Shanghai.”
In 2008, Hua Lian distributed contaminated leukemia drugs that paralyzed at least 200 Chinese cancer patients, according to a report published in the New York Times. The contaminated drug problem was such a concern that even abortion corporation Planned Parenthood called on FDA officials to investigate, writing, “The New York Times reported last week that Shanghai Pharmaceutical Group, and its subdivision, Shanghai Hualian, are under investigation for producing tainted leukemia drugs in China. Reports indicate that these drugs were not imported into the United States and that no other drugs produced by the company have been found to be faulty. Among the many drugs produced by Shanghai Hualian is mifepristone, one of two drugs used in medication abortion.”
Generic abortion pill tablets from India
On April 11, 2019, the FDA approved GenBioPro, Inc.’s abbreviated new drug application for a generic Mifeprex. A May 2020 import report published at the FDA website shows that at one time GenBioPro received mifepristone tablets from Sun Pharmaceuticals Industries, LTD. The bill of lading import record shows the abortion drugs were shipped from Sun Pharmaceuticals’ Mumbai location after departing from a port in Nhava Sheva, India. The drugs were shipped to GenBioPro’s Nevada office in Las Vegas after landing at a port in the New York/Newark Area of Newark, New Jersey, according to a previous Live Action News report.
While Sun Pharma manufactures abortion drugs for a number of countries, it also manufactures the UK version of the abortion pill called “Medabon – Combipack” under the subsidiary Ranbaxy UK. In an unrelated matter in 2013, Ranbaxy USA pleaded guilty to felony charges relating to the manufacture and distribution of certain adulterated drugs made at two of Ranbaxy’s manufacturing facilities in India and knowingly making material false statements to the FDA. According to Reuters, Sun Pharma acquired Ranbaxy in 2014 but the pharmaceutical company’s website states the merger was completed in March of 2015.
Ample supply of pills post-Roe
A majority (54%) of all abortions are committed by the abortion pill, according to 2020 preliminary data from the Guttmacher Institute. As a result, the abortion industry is estimated to be grossing $300 million annually from abortion pill sales. But should the Court overturn Roe v. Wade, abortion pill sales are expected to skyrocket.
Danco admitted to ABC News that they have an ample supply of abortion pills should the demand surge following a Supreme Court opinion in the Dobbs v. Jackson Women’s Health Organization case.
“We are prepared for any surge,” the unnamed spokesperson for Danco Laboratories said. “Our supply is stable and plentiful.”
Danco also told ABC that it’s working with federal regulators to make the drug available in pharmacies by the end of the year.
The abortion pill (Mifeprex or mifepristone) has tragically ended the lives of nearly five million preborn babies since 2000 when it was approved for use in a regimen with misoprostol. Following serious adverse events and even deaths, the drug was placed under a safety system known as REMS, which was weakened last year when the Biden FDA allowed the drug to be permanently shipped by mail.
As a result of the changes, all an aspiring abortion industry opportunist needs to sell abortion pills is a phone, a computer, and a partnership with an online pharmacy. This enables abortion facilities to increase profits by eliminating facilities and staff as well as testing and labs, and drastically reducing the time spent with clients.
“Like” Live Action News on Facebook for more pro-life news and commentary!
